Trial reportLeukemia research2018
Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.
Open access · greenAbstract readClinical TrialMulticenter Study
In one paragraph
Trial report in Leukemia research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update.Transplantation and cellular therapy · 2024Guideline
- Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.The New England journal of medicine · 2022Trial
- Article
- Allogeneic hematopoietic cell transplantation for therapy-related hematological malignancies in patients with multiple myeloma.Frontiers in oncology · 2026Article
- Therapy-related B-cell acute lymphoblastic leukemia after treatment for multiple myeloma.American journal of blood research · 2026Article
- Chimera's curse: myeloid clonal evolution after CD19-directed chimeric antigen receptor T-cell therapy.Haematologica · 2025Article
- Clonal evolution and the risk of secondary myeloid neoplasia following chimeric antigen receptor T-cell therapy.Haematologica · 2025Article
- Article
- Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy?Blood advances · 2025Review
- Characteristics and outcomes of therapy-related acute leukemia following autologous transplant (Auto-HCT) for multiple myeloma.Bone marrow transplantation · 2025Article
- Case Report: Secondary myelodysplastic syndrome following autologous stem cell transplantation in a patient with POEMS syndrome.Frontiers in immunology · 2025Article
- Risk of second primary cancers in nodal non-Hodgkin lymphoma patients by primary lymph node location: a retrospective cohort population-based study.Annals of medicine and surgery (2012) · 2024Article
- Article
- International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update.Bone marrow transplantation · 2024Review
- Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.Bone marrow transplantation · 2024Article
- Review
- The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant.Blood cancer journal · 2023Article
- Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.Blood advances · 2023Article
- Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective.Leukemia · 2023Article
- Clinical Characteristics and Prognosis of Secondary Acute Lymphoblastic Leukemia in Patients with Multiple Myeloma during Long-Term Thalidomide Maintenance.Journal of personalized medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
60 authors at 20 institutions in 8 countries.
Tomas RadivoyevitchDepartments of Quantitative Health Sciences and Translational Hematology & Oncology Research, Cleveland Clinic Foundation, Cleveland, OH, United States.
Robert M DeanBlood & Marrow Transplant Program, Cleveland Clinic, Cleveland, Ohio, United States.
Bronwen E ShawCIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI, United States. Electronic address: beshaw@mcw.edu.
Ruta BrazauskasCIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI, United States; Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI, United States.
Heather R TeccaCIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI, United States.
Remco J MolenaarDepartments of Quantitative Health Sciences and Translational Hematology & Oncology Research, Cleveland Clinic Foundation, Cleveland, OH, United States; Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands.
Minoo BattiwallaHematology Branch, National Heart, Lung and Blood Institute, Bethesda, MD, United States.
Bipin N SavaniDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Mary E D FlowersClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.
Kenneth R CookePediatric Blood and Marrow Transplantation Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States.
Betty K HamiltonBlood & Marrow Transplant Program, Cleveland Clinic, Cleveland, Ohio, United States.
Matt KalaycioBlood & Marrow Transplant Program, Cleveland Clinic, Cleveland, Ohio, United States.
Jaroslaw P MaciejewskiBlood & Marrow Transplant Program, Cleveland Clinic, Cleveland, Ohio, United States.
Ibrahim AhmedDepartment of Hematology Oncology and Bone Marrow Transplantation, The Children's Mercy Hospitals and Clinics, Kansas City, MO, United States.
Görgün AkpekStem Cell Transplantation and Cell Therapy, Rush University Medical Center, Chicago, IL, United States.
Ashish BajelRoyal Melbourne Hospital City Campus, Melbourne, Australia.
David BuchbinderDivision of Pediatrics Hematology, Children's Hospital of Orange County, Orange, CA, United States.
Jean-Yves CahnDepartment of Hematology, CHU Grenoble Alpes, Grenoble, France.
Anita D'SouzaCIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI, United States.
Andrew DalyTom Baker Cancer Center, Calgary, AB, Canada.
Zachariah DeFilippBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, United States.
Siddhartha GangulyBlood and Marrow Transplantation, University of Kansas Medical Center, Kansas City, KS, United States.
Mehdi HamadaniCIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI, United States.
Robert J HayashiDepartment of Pediatrics, Washington University School of Medicine in St. Louis, St. Louis, MO, United States.
Peiman HemattiDepartment of Medicine, University of Wisconsin Hospital and Clinics, Madison, WI, United States.
Yoshihiro InamotoDivision of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Nandita KheraDepartment of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, United States.
Tamila Kindwall-KellerDivision of Hematology/Oncology, University of Virginia Health System, Charlottesville, VA, United States.
Heather LandauBone Marrow Transplant Service, Division of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Hillard LazarusSeidman Cancer Center, Case Western Reserve University, Cleveland, OH, United States.
Navneet S MajhailBlood & Marrow Transplant Program, Cleveland Clinic, Cleveland, Ohio, United States.
David I MarksAdult Bone Marrow Transplant, University Hospitals Bristol NHS Trust, Bristol, United Kingdom.
Richard F OlssonDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; Centre for Clinical Research Sormland, Uppsala University, Uppsala, Sweden.
Sachiko SeoDepartment of Hematology & Oncology, National Cancer Research Center East, Chiba, Japan.
Amir SteinbergDepartment of Hematology-Oncology, Mount Sinai Hospital, New York, NY, United States.
Basem M WilliamOhio State Medical Center, Columbus, OH, United States.
Baldeep WirkDivision of Bone Marrow Transplant, Seattle Cancer Care Alliance, Seattle, WA, United States.
Jean A YaredDepartment of Medicine, University of Maryland, Baltimore, MD, United States.
Mahmoud AljurfDepartment of Oncology, King Faisal Specialist Hospital, Riyadh, Saudi Arabia.
Muneer H AbidiDepartment of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, United States.
Heather AlleweltDuke University Medical Center, Durham, NC, United States.
Amer BeitinjanehUniversity of Miami, Miami, FL, United States.
Rachel CookOregon Health and Science University, Portland, OR, United States.
Robert F CornellDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
Joseph W FayBaylor University Medical Center, Dallas, TX, United States.
Gregory HaleDepartment of Hematology/Oncology, Johns Hopkins All Children's Hospital, St. Petersburg, FL, United States.
Jennifer Holter ChakrabartyDepartment of Hematology/Oncology, University of Oklahoma, Oklahoma City, OK, United States.
Sonata JodeleCincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Kimberly A KasowUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Anuj MahindraScripps Blood & Marrow Transplant Program, La Jolla, CA, United States.
Adriana K MaloneTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; United States.
Uday PopatMD Anderson Cancer Center, Houston, TX, United States.
J Douglas RizzoCIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, WI, United States.
Harry C SchoutenDepartment of Hematology, Academische Ziekenhuis, Maastricht, Netherlands.
Anne B WarwickDepartment of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.
William A WoodUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
Mikkael A SekeresBlood & Marrow Transplant Program, Cleveland Clinic, Cleveland, Ohio, United States.
Mark R LitzowDept. Of Medicine, Mayo Clinic, Rochester, MN, United States.
Robert P GaleDepartment of Medicine, Imperial College London, London, United Kingdom.
Shahrukh K HashmiDepartment of Oncology, King Faisal Specialist Hospital, Riyadh, Saudi Arabia.
Cleveland Clinic · USMedical College of Wisconsin · USKing Faisal Specialist Hospital & Research Centre · SAUniversity of North Carolina at Chapel Hill · USVanderbilt University Medical Center · USBaylor University Medical Center · USCentre Hospitalier Universitaire de Grenoble · FRChildren's Hospital of Orange County · USChildren's Mercy Hospital · USCincinnati Children's Hospital Medical Center · USFred Hutch Cancer Center · USImperial College London · GBJohns Hopkins University · USMassachusetts General Hospital · USMayo Clinic · USMayo Clinic Hospital · USMemorial Sloan Kettering Cancer Center · USMount Sinai Hospital · USNational Cancer Center Hospital East · JPNational Heart Lung and Blood Institute · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MData Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MEasy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8MNCI NIH HHS P30 CA008748NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069294
Abstract
backgroundExposures to DNA-damaging drugs and ionizing radiations increase risks of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
methods9028 recipients of hematopoietic cell autotransplants (1995-2010) for Hodgkin lymphoma (HL; n = 916), non-Hodgkin lymphoma (NHL; n = 3546) and plasma cell myeloma (PCM; n = 4566), reported to the CIBMTR, were analyzed for risk of subsequent AML or MDS.
results335 MDS/AML cases were diagnosed posttransplant (3.7%). Variables associated with an increased risk for AML or MDS in multivariate analyses were: (1) conditioning with total body radiation versus chemotherapy alone for HL (HR = 4.0; 95% confidence interval [1.4, 11.6]) and NHL (HR = 2.5 [1.1, 2.5]); (2) ≥3 versus 1 line of chemotherapy for NHL (HR = 1.9 [1.3, 2.8]); and (3) subjects with NHL transplanted in 2005-2010 versus 1995-1999 (HR = 2.1 [1.5, 3.1]). Using Surveillance, Epidemiology and End Results (SEER) data, we found risks for AML/MDS in HL, NHL and PCM to be 5-10 times the background rate. In contrast, relative risks were 10-50 for AML and approximately 100 for MDS in the autotransplant cohort.
conclusionsThere are substantial risks of AML and MDS after autotransplants for HL, NHL and PCM.
Indexed as
Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteLeukemia, Plasma CellMyelodysplastic SyndromesNeoplasms, Second PrimaryAdolescentAdultAgedFemaleHumansLymphomaMaleMiddle AgedRisk FactorsTransplantation, AutologousAMLAutotransplantCIBMTRMDSNew cancersSEERTherapy-related
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.